Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
Recruiting now · Phase 1
Conditions studied: Multiple Myeloma
In brief
KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy of KSVCBD injection in patients with relapsed or refractory (r/r) multiple myeloma(MM) expressing CD19 and/or BCMA.
Key facts
- Study ID
- NCT07620275
- Run by
- Chinese PLA General Hospital
- People needed
- 9
- Starts
- 2026-06-10
- Expected to finish
- 2029-03-15
- Last updated by the study team
- 2026-06-02
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Biotherapeutic Department of Chinese PLA General Hospital — Beijing, Beijing Municipality, China (enrolling)
- Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University — Beijing, China
- National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College — Tianjin, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.